🇺🇸 FDA

Company profile · Sponsor

Biocryst

BCRX · NYSE pharma DURHAM, NC, EU
Pipeline
24
Drugs
3
Patents
8

Quick answer

Biocryst (BCRX) is a pharma company. headquartered in DURHAM, NC, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker BCRX
Exchange NYSE
Company type pharma
Headquarters DURHAM, NC, EU
SEC CIK 0000882796

Pipeline (24)

Search pipeline →

  1. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  2. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  3. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  4. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  5. Peramivir

    Biocryst

    Seasonal Influenza

    phase 3 small molecule completed

    1 trial

  6. Peramivir

    Biocryst

    Influenza

    phase 3 small molecule completed

    5 trials

  7. Peramivir 150mg

    Biocryst

    Influenza

    phase 3 small molecule terminated

    1 trial

  8. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  9. avoralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule terminated

    1 trial

  10. berotralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  11. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  12. BCX7353

    Biocryst

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    2 trials

  13. BCX9930

    Biocryst

    Complement 3 Glomerulopathy

    phase 2 small molecule terminated

    1 trial

  14. BCX9930

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule terminated

    3 trials

  15. Eculizumab

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  16. Forodesine 200 mg

    Biocryst

    Cutaneous T-cell Lymphoma (CTCL),

    phase 2 small molecule completed

    1 trial

  17. Forodesine Hydrochloride Sterile Solution, 5 mg/mL

    Biocryst

    Leukemia

    phase 2 small molecule terminated

    1 trial

  18. Peramivir

    Biocryst

    Acute, Uncomplicated Human Influenza

    phase 2 small molecule completed

    1 trial

  19. Peramivir 150 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  20. Peramivir 200 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  21. Placebo

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  22. Placebo

    Biocryst

    Gout

    phase 2 small molecule completed

    3 trials

  23. forodesine HCl

    Biocryst

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  24. forodesine hydrochloride

    Biocryst

    Lymphoma

    phase 2 small molecule completed

    2 trials

Drugs (3)

Search drugs →

  1. berotralstat

    ORLADEYO

    B06AC

  2. berotralstat dihydrochloride

    ORLADEYO

    ORAL approved

  3. peramivir

    ALPIVAB

    INTRAVENOUS approved

    J05AH03

Patents (8)

Search patents →

  1. US 12344585

    Crystalline salts of a plasma kallikrein inhibitor

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12162838

    Human plasma kallikrein inhibitors

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12121503

    Antiviral treatments

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12116346

    Human plasma kallikrein inhibitors

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12043610

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11975003

    Methods and compositions for treatment of Zika virus infection

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11866418

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Biocryst?

Biocryst (BCRX) is a pharma company. headquartered in DURHAM, NC, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Biocryst sponsor?

We track 24 ClinicalTrials.gov-linked programs for Biocryst, including BCX4161 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Biocryst company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.